Home
BLUE
BLUE News

Latest bluebird bio Inc. (BLUE) News on May 14, 2025

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

Business Wire

11 hours ago

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Business Wire

5 days ago

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

Business Wire

9 days ago

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Business Wire

a month ago

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

MT Newswires

2 months ago

Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Business Wire

2 months ago

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

Struggling bluebird bio to go private for less than $30m

Pharmaceutical Technology

3 months ago

Struggling bluebird bio to go private for less than $30m

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

Benzinga

3 months ago

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Business Wire

3 months ago

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

5 months ago

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire

5 months ago

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Business Wire

5 months ago

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces 1-for-20 Reverse Stock Split

Business Wire

5 months ago

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Business Wire

5 months ago

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

Benzinga

6 months ago

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

6 months ago

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

Benzinga

6 months ago

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

GuruFocus.com

6 months ago

bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

Zacks

6 months ago

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

6 months ago

Bluebird: Q3 Earnings Snapshot

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Business Wire

6 months ago

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Business Wire

6 months ago

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire

6 months ago

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

Insider Monkey

6 months ago

bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy

Benzinga

7 months ago

Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy

Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials

Pharmaceutical Technology

7 months ago

Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Associated Press Finance

8 months ago

Bluebird: Q2 Earnings Snapshot

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Business Wire

8 months ago

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year

Benzinga

8 months ago

Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year

MT Newswires

8 months ago

Bluebird Bio to Reduce Workforce by 25% as Part of Restructuring

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Business Wire

8 months ago

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Associated Press Finance

8 months ago

Bluebird: Q1 Earnings Snapshot

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Business Wire

8 months ago

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date

Pharmaceutical Technology

9 months ago

FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date

bluebird bio Announces September Investor Events

Business Wire

9 months ago

bluebird bio Announces September Investor Events

MT Newswires

9 months ago

bluebird bio Gets Nasdaq Noncompliance Notice

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Business Wire

9 months ago

bluebird bio Announces Receipt of Expected Notices from Nasdaq

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Business Wire

9 months ago

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Announces Second Quarter 2024 Results Call Date

Business Wire

9 months ago

bluebird bio Announces Second Quarter 2024 Results Call Date

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

With 57% ownership of the shares, bluebird bio, Inc. (NASDAQ:BLUE) is heavily dominated by institutional owners

Simply Wall St.

10 months ago

With 57% ownership of the shares, bluebird bio, Inc. (NASDAQ:BLUE) is heavily dominated by institutional owners

HHS gives thumbs down to bluebird’s fertility support programme

Pharmaceutical Technology

10 months ago

HHS gives thumbs down to bluebird’s fertility support programme

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

PR Newswire

a year ago

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

bluebird bio Appoints O. James Sterling as Chief Financial Officer

Business Wire

a year ago

bluebird bio Appoints O. James Sterling as Chief Financial Officer

BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?

TipRanks

a year ago

BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?

Is Bluebird Bio Stock a Buy?

Motley Fool

a year ago

Is Bluebird Bio Stock a Buy?

GuruFocus.com

a year ago

bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

Zacks

a year ago

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Business Wire

a year ago

bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events

Business Wire

a year ago

bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events

bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy

Business Wire

a year ago

bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy

MT Newswires

a year ago

bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report

bluebird bio Announces Receipt of Expected Notice from Nasdaq

Business Wire

a year ago

bluebird bio Announces Receipt of Expected Notice from Nasdaq

Is Bluebird Bio Stock a Buy?

Motley Fool

a year ago

Is Bluebird Bio Stock a Buy?

Better Buy: Bluebird Bio Vs. Novavax

Motley Fool

a year ago

Better Buy: Bluebird Bio Vs. Novavax

Is This Beaten-Down Stock a Good Acquisition Target?

Motley Fool

a year ago

Is This Beaten-Down Stock a Good Acquisition Target?

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript

Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst

Motley Fool

a year ago

Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst

bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

Business Wire

a year ago

bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call

Business Wire

a year ago

bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call

Why Bluebird Bio Stock Flew Higher Than the Market Today

Motley Fool

a year ago

Why Bluebird Bio Stock Flew Higher Than the Market Today

bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

Business Wire

a year ago

bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

Is Bluebird Bio Stock a Buy Now?

Motley Fool

a year ago

Is Bluebird Bio Stock a Buy Now?

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

Business Wire

a year ago

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

Why Bluebird Bio Stock Dived Into the Red on Tuesday

Motley Fool

a year ago

Why Bluebird Bio Stock Dived Into the Red on Tuesday

bluebird bio, Inc.'s (NASDAQ:BLUE) top owners are retail investors with 51% stake, while 49% is held by institutions

Simply Wall St.

a year ago

bluebird bio, Inc.'s (NASDAQ:BLUE) top owners are retail investors with 51% stake, while 49% is held by institutions

RADIANT LOGISTICS TO HOST INVESTOR CALL TO DISCUSS FINANCIAL RESULTS FOR SECOND FISCAL QUARTER ENDED DECEMBER 31, 2023

PR Newswire

a year ago

RADIANT LOGISTICS TO HOST INVESTOR CALL TO DISCUSS FINANCIAL RESULTS FOR SECOND FISCAL QUARTER ENDED DECEMBER 31, 2023

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?

Ring Energy Announces Production Results and Continued Debt Reduction for Fourth Quarter 2023 and Partial Guidance for the First Quarter 2024

GlobeNewswire

a year ago

Ring Energy Announces Production Results and Continued Debt Reduction for Fourth Quarter 2023 and Partial Guidance for the First Quarter 2024

If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today

Motley Fool

a year ago

If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today

Viemed Healthcare, Inc.'s (NASDAQ:VMD) institutional shareholders had a great week as one-year returns increased after a 12% gain last week

Simply Wall St.

a year ago

Viemed Healthcare, Inc.'s (NASDAQ:VMD) institutional shareholders had a great week as one-year returns increased after a 12% gain last week

Heritage Commerce Corp Earns $13.3 Million for the Fourth Quarter of 2023, and $64.4 Million for the Full Year 2023

GlobeNewswire

a year ago

Heritage Commerce Corp Earns $13.3 Million for the Fourth Quarter of 2023, and $64.4 Million for the Full Year 2023

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

PR Newswire

a year ago

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

GlobeNewswire

a year ago

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 23, 2024

Banner (BANR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

a year ago

Banner (BANR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

NGL Energy Partners LP Announces $700 Million Senior Secured Term Loan Facility and Provides Financial Update

Business Wire

a year ago

NGL Energy Partners LP Announces $700 Million Senior Secured Term Loan Facility and Provides Financial Update

2 Red Flags for Bluebird Bio Stock

Motley Fool

a year ago

2 Red Flags for Bluebird Bio Stock

Univest Financial Corporation to Hold Fourth Quarter 2023 Earnings Call

GlobeNewswire

a year ago

Univest Financial Corporation to Hold Fourth Quarter 2023 Earnings Call

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

Business Wire

a year ago

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Leftovers: Dunkin’ muscles into protein powder | Danone whips up International Delight cold foam creamer

Food Dive

a year ago

Leftovers: Dunkin’ muscles into protein powder | Danone whips up International Delight cold foam creamer

Bluebird’s Plans to Win in Sickle Cell Come Into Focus

The Wall Street Journal

a year ago

Bluebird’s Plans to Win in Sickle Cell Come Into Focus

When Will Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Turn A Profit?

Simply Wall St.

a year ago

When Will Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Turn A Profit?

Absci to Participate in the 26th Annual Needham Growth Conference

GlobeNewswire

a year ago

Absci to Participate in the 26th Annual Needham Growth Conference

Better Risky Investment: Bluebird Bio vs. Shiba Inu

Motley Fool

a year ago

Better Risky Investment: Bluebird Bio vs. Shiba Inu

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

a year ago

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

GlobeNewswire

a year ago

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

Opthea to Receive US$35M Commitment and Additional US$50M Funding

GlobeNewswire

a year ago

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Should You Invest in Bluebird Bio Right Now?

Motley Fool

a year ago

Should You Invest in Bluebird Bio Right Now?

Mission Produce, Inc. (NASDAQ:AVO) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Mission Produce, Inc. (NASDAQ:AVO) Q4 2023 Earnings Call Transcript

Should You Investigate The Shyft Group, Inc. (NASDAQ:SHYF) At US$12.76?

Simply Wall St.

a year ago

Should You Investigate The Shyft Group, Inc. (NASDAQ:SHYF) At US$12.76?

Gold Royalty Completes Acquisition of Québec Royalty Portfolio

CNW Group

a year ago

Gold Royalty Completes Acquisition of Québec Royalty Portfolio

Mission Produce (NASDAQ:AVO) Misses Q4 Sales Targets

StockStory

a year ago

Mission Produce (NASDAQ:AVO) Misses Q4 Sales Targets

Business Wire

a year ago

Mitek Appoints David Lyle as Chief Financial Officer

Opthea Receives A$8.8 million R&D Tax Incentive

GlobeNewswire

a year ago

Opthea Receives A$8.8 million R&D Tax Incentive

Business Wire

a year ago

Mitek Announces Receipt of Notice from Nasdaq

Share on Social Networks: